Recent Advances in Oral and Transdermal Contraception

Peggy Piascik, PhD

Disclosures

US Pharmacist. 2008;33(9):19-23. 

In This Article

Desogestrel-containing Oral Contraceptives

Desogestrel is a third-generation progestin that is found in a number of COCs, including Cyclessa, Ortho-Cept, Mircette, and Desogen. The third-generation products were developed during the 1980s to decrease the androgenic effects, including hirsutism and acne, commonly seen with earlier generations of oral contraceptives. Two meta-analyses published in 2001 concluded that desogestrel- containing oral contraceptives increase the risk of thromboembolism by a factor of 1.7 over products that contain levonorgestrel.[14,15]

The FDA requires manufacturers of desogestrel-containing products to include a statement in the Warnings section of COC labeling that these products are associated with a two-fold increase in the risk of venous thromboembolism. According to the FDA, patients at increased risk for thromboembolism should consider switching to a second-generation product.[16] The Public Citizen's Health Research Group (PCHRG) filed a petition with the FDA in February 2007 to remove desogestrel because of the increased risk of developing blood clots.[17] The petition claims that the third-generation products confer no clear advantage over older oral contraceptives that is sufficient to warrant the risks.[17]

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....